ARCH Venture funds add Lyell (LYEL) stake with 488,090-share buy
Rhea-AI Filing Summary
ARCH Venture funds increased their indirect stake in Lyell Immunopharma, Inc. by purchasing 488,090 shares of common stock in an open-market transaction on March 6, 2026, at $25.61 per share. The filing attributes ownership to ARCH Venture Fund IX-affiliated limited partnerships, with the general partner and managing directors disclaiming beneficial ownership beyond their pecuniary interests.
Positive
- None.
Negative
- None.
Insights
ARCH Venture funds disclosed a sizable open-market purchase in Lyell shares.
The Form 4 shows ARCH Venture Fund IX-affiliated entities indirectly acquiring 488,090 shares of Lyell Immunopharma common stock at $25.61 per share in an open-market transaction on March 6, 2026. The reporting structure runs through multiple ARCH general-partner entities.
Footnotes clarify that the shares are directly held by ARCH limited partnerships, and the general partners and managing directors disclaim beneficial ownership except for any pecuniary interest. This means economic exposure sits primarily at the fund level, with governance influence mediated through those partnerships.
The disclosure updates Lyell’s ownership picture by documenting additional indirect holdings by a more-than-ten-percent owner group. Future company filings may further detail how these fund-level positions evolve over time and how overall ownership concentration among major holders changes.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 488,090 | $25.61 | $12.50M |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- These shares are directly held by ARCH Venture Fund XIII, L.P. ("ARCH XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP") is the general partner of ARCH XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC") is the general partner of AVP XIII LP. Keith Crandell, Robert Nelsen, Kristina Burow, Paul Berns and Steven Gillis are members of the investment committee of AVP XIII LLC (the "AVP XIII LLC Committee Members"). Each of AVP XIII LP and AVP XIII LLC may be deemed to beneficially own the shares held by ARCH XIII, and each of the AVP XIII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIII. Each of AVP XIII LP, AVP XIII LLC and the AVP XIII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. These shares are directly held by ARCH Venture Fund IX, L.P. ("ARCH IX"). ARCH Venture Partners IX, L.P. ("GPLP"), as the sole general partner of ARCH IX, may be deemed to beneficially own the shares held by ARCH IX. ARCH Venture Partners IX, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by ARCH IX. As managing directors of GPLLC, each of Keith Crandell, Robert Nelsen and Clinton Bybee (the "ARCH Managing Directors"), may be deemed to beneficially own the shares held by ARCH IX. Each of GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any. These shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. GPLLC, as the sole general partner of Overage GPLP, may be deemed to beneficially own the shares held by ARCH Overage. As managing directors of GPLLC, each of the ARCH Managing Directors may be deemed to beneficially own the shares held by ARCH Overage. Each of Overage GPLP, GPLLC and the ARCH Managing Directors disclaims beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein, if any.
